Evidence map›Paper›PMID 38519056›Full record

ArticleJournal for immunotherapy of cancer2024

SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.

Michael T Lotze, Tricia Cottrell, Carlo Bifulco, Laura Chow, Leslie Cope, Sacha Gnjatic, Holden T Maecker, Joe Yeong Poh Shen

Erratum issuedAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Perspectives from the leadership ofJournal for immunotherapy of cancer · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Michael T LotzeHillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA lotzemt@upmc.edu.
Tricia CottrellQueen's University Cancer Research Institute, Kingston, Ontario, Canada.
Carlo BifulcoProvidence Portland Medical Center, Portland, Oregon, USA.
Laura ChowThe University of Texas at Austin Dell Medical School, Austin, Texas, USA.
Leslie CopeJohns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Sacha GnjaticIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Holden T MaeckerStanford University School of Medicine, Stanford, California, USA.
Joe Yeong Poh ShenDivision of Pathology, Singapore General Hospital, Singapore.

Funding

High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5M
Stanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9M
NCI NIH HHS U24 CA224309NCI NIH HHS U24 CA224319
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsBiomarkersClinical Trials as TopicHumansMedical OncologyBiomarkersBiomarkerBiopsyCirculating tumor DNA - ctDNAEducationPathology

Identifiers

PMID38519056
PMCPMC10961490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.